GTC Biotherapeutics (fka GTCB)

[acgood]

I think the question was in regard to the financial terms of the partnership.

Here is the detail from the 10-k filing:

ATryn ® : We have established a collaboration agreement with LEO for further development and commercialization of ATryn ® in Europe, Canada, and the Middle East. LEO has selected disseminated intravascular coagulation, or DIC, associated with severe sepsis as an acquired antithrombin deficiency indication for development in Europe. LEO has obtained scientific advice from the European Medicines Agency, or EMEA, on the design of a Phase II dose ranging study of approximately 200 patients. Initial clinical sites are opening, and we anticipate patient enrollment lasting 12 months and results being available in mid-2008. We will have the right to use the Phase II data in the U.S. and all other territories outside of LEO’s territories. LEO plans to seek further advice from the EMEA for a potential Phase III study once the Phase II data is available. We will supply the product for these clinical studies and receive payment for delivery of the material to LEO. We will receive a transfer price and royalties on commercial sales of ATryn ® by LEO.